Featured* Open Trials

Last Updated: April 2026

*The following list is NOT comprehensive and highlights featured trials only.
Please contact Research Manager, Noura Sall (research@stcharleshealthcare.org or 541-706-6362), to inquire about all currently available trials.

Non-cancer related trials

Study Name	Synopsis	Key Eligibility Criteria	Notes
STEMCELL	Umbilical cord blood collection for storage to provide to various commercial and educational organizations for their scientific and medical research and education.	• 18 years of age or older • 32+ weeks gestation • HIV, Hepatitis B & C negative	○ All personal identifiers will be removed from your blood sample and your baby's donated umbilical cord blood sample. It will then be distributed for future research without additional informed consent from you. ○ No blood samples collected through this study will be used for any in vivo human scientific research. ○ At no time will your donated sample ever be placed into another individual.

Cancer related trials

Quality of Life / Post-treatment

Study Name	Synopsis	Key Eligibility Criteria	Notes
NRG-CC015 (HEAL-ABC)	Harnessing E-Mindfulness Approaches for Living After Breast Cancer	• History of stage 0-III, non-metastatic breast cancer • ≥ 18 and < 51 years of age at diagnosis • ≥ 6 months and < 5 years post-treatment • English or Spanish speaking	○ Study website (NRG-CC015 - NRG Oncology)

Breast Cancer			
Study Name	Synopsis	Key Eligibility Criteria	Notes
Gilead ASCENT-05	Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy	• Triple negative breast cancer (allows estrogen and/or progesterone receptor up to 10%) • Prior to surgery, chemotherapy with or without an Immune Checkpoint Inhibitor for a minimum of 6 cycles or 18 weeks. • Residual disease in breast or LN after surgery with negative margins (not stage IV)	○ Study website (https://www.ascent05.com/)
BR009 (OFSET)	Testing the addition of chemotherapy to the usual treatment of ovarian function suppression plus hormonal therapy in premenopausal ER+/HER2- breast cancer patients who are at high risk of cancer returning	• Premenopausal • Estrogen receptor positive and HER2 negative breast cancer • Up to 3 positive axillary lymph nodes • Oncotype Recurrence Score ≤25	○ Study website (https://www.nrgoncology.org/OFSET)
ShortStop HER2+	Among patients with early-stage HER2+ breast cancer who have a complete response after preoperative chemotherapy with trastuzumab, will 6 months of HER2-targeted medications be as effective as 12 months of HER2-targeted medications at preventing cancer from coming back?	• HER2-positive (HER2+) early stage breast cancer and have recently completed chemotherapy in combination with trastuzumab, followed by breast surgery. • The chemotherapy plus trastuzumab produced a pathologic complete response (pCR), meaning that no remaining cancer was found during your breast surgery.	○ If you decide to take part in this study, you will either get the HER2-targeted medication trastuzumab (with or without pertuzumab) for up to 51 weeks (approximately 12 months), or you will get the HER2-targeted medication trastuzumab (with or without pertuzumab) for up to 27 weeks (approximately 6 months). ○ After you finish your study treatment, your doctor will continue to follow your condition every 6 months for 5 years and watch you for side effects or cancer coming back. This means you will keep seeing your doctor for 5 years after treatment. After that, they will check on you every year for a total of 10 years after you enrolled on the study.

Lung Cancer

Study Name	Synopsis	Key Eligibility Criteria	Notes
Daiichi Sankyo DESTINY-Lung06	Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 overexpressing Non-Small Cell Lung Cancer (NSCLC)	• Newly diagnosed, untreated, locally advanced or metastatic non-squamous NSCLC that cannot be removed by surgery • Have enough tumor tissue to test for the presence of certain proteins	○ The DESTINY-Lung06 Study is researching an investigational medication for people with a certain type of (NSCLC). It is hoped that the investigational medication may help people live longer without their tumor growing or spreading.
Merck KANDLELIT-007	Clinical Study to Evaluate the Safety and Efficacy of MK-1084 (calderasib) in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/ Platinum Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC)	• Newly diagnosed with stage IV NSCLC • Have the KRAS G12C mutation • Not previously or currently treated for NSCLC	○ Researchers will compare these 2 investigational study treatments: ▪ Investigational combination of MK-1084 with MK-3475A ▪ Investigational combination of MK-3475A with chemotherapy

Hematologic (blood) Cancers

Study Name	Synopsis	Key Eligibility Criteria	Notes
S1925 (EVOLVE)	Among patients with newly diagnosed asymptomatic high-risk CLL/SLL, can starting venetoclax and obinutuzumab (called V-O) treatment early (before you have symptoms) help patients live longer than the usual approach of waiting to start treatment once symptoms appear?	• Have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) • Have no symptoms and do not need to start treatment now • Results of blood and other tests show that the cancer might be harder to treat than other similar cancers	○ Study website (https://www.swog.org/clinical-trials/s1925)